PlainPharmaWatch

CMS Open Payments · Tool

Penumbra, Inc. vs Exeltis, USA Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Exeltis, USA Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 519, versus 45 for the other company. Its single largest recorded recipient represents 0.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Penumbra, Inc.
HHI 45 · top recipient 0.0%
Ranked #1,772 of 1,838 companies by HHI
Exeltis, USA Inc.
HHI 519 · top recipient 0.2%
Ranked #1,278 of 1,838 companies by HHI

Payment Overview

Company A

Penumbra, Inc.

Total Payments
$7.7M
% of Industry
0.1%
Transactions
22,972
Avg per Transaction
$333.39
Recipients
22,427
Avg per Recipient
$341.49
Payment Types
5
Top Payment Type
Compensation for Services Other Than Consulting
Company B

Exeltis, USA Inc.

Total Payments
$7.7M
% of Industry
0.1%
Transactions
18,860
Avg per Transaction
$407.64
Recipients
17,662
Avg per Recipient
$435.29
Payment Types
4
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

Penumbra, Inc. vs Exeltis, USA Inc. - total reported payments in CMS Open Payments PY2024

Exeltis, USA Inc.$7.7MPenumbra, Inc.$7.7M

Payment Types Breakdown

Penumbra, Inc.

Compensation for Services Other Than Consulting $2.1M

27.8%

Travel and Lodging $1.7M

22.5%

Food and Beverage $1.5M

19.8%

Education $240.9K

3.1%

Consulting Fee $213.8K

2.8%

Exeltis, USA Inc.

Food and Beverage $345.7K

4.5%

Consulting Fee $205.3K

2.7%

Compensation for Services Other Than Consulting $139.2K

1.8%

Travel and Lodging $13.7K

0.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Penumbra, Inc.

  1. 1

    SANTHOSH J MATHEWS

    $168,990.31 · 114 txns

  2. 2

    DONALD FREI

    $151,154.09 · 84 txns

  3. 3

    FRANK R. ARKO

    $110,135.30 · 110 txns

  4. 4

    SAMEH SAYFO

    $88,354.11 · 58 txns

  5. 5

    Washington Hospital Center

    $78,000.00 · 3 txns

Exeltis, USA Inc.

  1. 1

    CATHERINE HANSEN

    $122,306.89 · 36 txns

  2. 2

    YOUSSEF MOUHAYAR

    $83,643.54 · 17 txns

  3. 3

    MICHAEL KRYCHMAN

    $46,946.13 · 1 txns

  4. 4

    JENNIFER ELLIOTT

    $27,208.29 · 11 txns

  5. 5

    JORDAN W NEIGHBORS

    $21,963.72 · 21 txns

Summary Comparison

Metric Penumbra, Inc. Exeltis, USA Inc.
Total Payments $7.7M $7.7M
% of Industry Total 0.1% 0.1%
Transaction Count 22,972 18,860
Avg per Transaction $333.39 $407.64
Recipient Count 22,427 17,662
Avg per Recipient $341.49 $435.29
Payment Type Count 5 4
Top Payment Type Compensation for Services Other Than Consulting Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.